Advancing Service Integration in Opioid Treatment Progams for the Care and Treatment of Hepatitis C Infection

Download Download as PDF (Size:142KB)  HTML    PP. 118-125  
DOI: 10.4236/ijcm.2014.53020    2,554 Downloads   4,073 Views   Citations

ABSTRACT


It is estimated that approximately 200 million people globally are infected with the hepatitis C virus and that roughly half of these people live in Asia. Without treatment, it is estimated that roughly twenty percent of those infected with hepatitis C virus progress to chronic liver disease, then subsequently, end-stage liver disease. Thus, access to hepatitis C testing and subsequent care and treatment of chronic hepatitis C infection are essential to address the global burden of disease. In the United States, the Center for Disease Control and Prevention estimates that 60% of new cases of hepatitis infection are due to injection drug use. Opioid Treatment Programs (OTP’s) dispense methadone and buprenorphine under specific federal regulations to injection drug users diagnosed with opioid dependence. OTPs are developing comprehensive care and treatment model programs that integrate general medical and infectious disease-related medical care with substance abuse and mental health services. Integrating hepatitis care services and treatment in the substance abuse treatment settings foster access to care for patients with hepatitis C infection, many who otherwise would not receive needed care and treatment. This may serve as a national model for highly cost-efficient healthcare that has a measurable outcome of improved public health with reduced hepatitis C prevalence.


Cite this paper

T. Kresina, R. Lubran, H. Clark and E. McCance-Katz, "Advancing Service Integration in Opioid Treatment Progams for the Care and Treatment of Hepatitis C Infection," International Journal of Clinical Medicine, Vol. 5 No. 3, 2014, pp. 118-125. doi: 10.4236/ijcm.2014.53020.

References

[1] L. Degenhart, H. A. Whiteford, A. J. Ferrari, A. J. Baxter, F. J. Charlson and W. D. Hall, “Global Burden of Disease Attributable to Illicit Drug Use and Dependence: Findings From the Global Burden of Disease Study 2010,” Lancet, Vol. 382, No. 9904, 2013, pp. 1564-1574.
http://dx.doi.org/10.1016/S0140-6736(13)61530-5
[2] M. J. Kreek, O. Levran, B. Reed, S. D. Schlussman, Y Zhou and E. R. Butelman. “Opiate Addiction and Cocaine Addiction: Underlying Molecular Neurobiology and Genetics,” Journal of Clinical Investigation, Vol. 122, No. 10, 2012, pp. 3387-3393.
http://dx.doi.org/10.1172/JCI60390
[3] CDC (Centers for Disease Control and Prevention), “Hepatitis Surveillance Report No. 59,” United States Department of Health and Human Services. Centers for Disease Control and Prevention, Atlanta. 2004.
www.cdc.gov/hepatitis
[4] Substance Abuse and Mental Health Services Administration (SAMHSA), “National Survey on Drug Use and Health,” DHHS, Rockville, 2004.
http://oas.samhsa.gov/NSDUH/2k4nsduh/2k4tabs/toc
[5] ONDCP (Office of National Drug Control Policy), “Drug Abuse in America,” Office of National Drug Control Policy, Washington DC, 2002.
http://www.whitehousedrugpolicy.gov
[6] E. Puigdollers, A. Domingo-Salvany and M. T. Brugal “Characteristics of Heroin Addicts Entering Methadone Maintenance Treatment: Quality of Life and Gender,” Substance Use & Misuse, Vol. 39, No. 9, 2004, pp. 1353-1368. http://dx.doi.org/10.1081/JA-120039392
[7] P. Millson, L. Challacombe, P. J. Villeneuve, C. J. Strike, B. Fischer and T. Myers. “Determinants of Health-Related Quality of Life of Opiate Users at Entry to Low-Threshold Methadone Programs,” European Addiction Research, Vol. 12, 2006, pp. 74-82.
http://dx.doi.org/10.1159/000090426
[8] P.E. Millson, L. Challacombe and P. J. Villeneuve, “Self-Perceived Health Among Canadian Opiate Users: A Comparison to the General Population and to Other Chronic Disease Populations.” Canadian Journal of Public Health, Vol. 95, 2004, pp. 99-103.
[9] Y. Mizuno, D. Purcell, T. M. Borkowski, K. Knight and the SUDIS Team, “The Life Priorities of HIV-Seropositive Injection Drug Users: Findings from a Community-Based Sample,” AIDS and Behavior, Vol. 7, No. 4, 2003, pp. 395-403.
http://dx.doi.org/10.1023/B:AIBE.0000004731.94734.77
[10] J. Bell and D. Zador, “A Risk-Benefit Analysis of Methadone Maintenance Treatment,” Drug Safety, Vol. 22, No. 3, 2000, pp. 179-190.
http://dx.doi.org/10.2165/00002018-200022030-00002
[11] S. M. Giacomuzzi, M. Ertl, G. Kemmler, Y. Riemer and A. Vigl, “Sublingual Buprenorphine and Methadone Maintenance Treatment: A Three Year Follow-Up of Quality of Life Assessment,” The Scientific World Journal, Vol. 5, 2005, pp. 452-468.
http://dx.doi.org/10.1100/tsw.2005.52
[12] V. Giedrius, Z. Padaiga and E. Bagdonas. “Cost-Utility Analysis of Methadone Maintenance Treatment: A Methodological Approach,” Substance Use & Misuse, Vol. 41, No. 1, 2006, pp. 87-101.
http://dx.doi.org/10.1080/10826080500368751
[13] Office of National Drug Control Policy (ONDCP), “Methadone. Fact Sheet,” Office of National Drug Control Policy, Washington DC, 2000.
http://www.whitehousedrugpolicy.gov
[14] L. Gowing, M. Farrell, R. Bornemann and R. Ali. “Substitution Treatment of Injecting Opioid Users for Prevention of HIV Infection,” The Cochrane Database of Systematic Reviews, 2004, Article ID: CD004145.
[15] R. E. Johnson and J. C. McCaugh, “Buprenorphine and Naloxone for Heroin Dependence,” Current Psychiatry Reports, Vol. 2, 2000, pp. 519-526.
http://dx.doi.org/10.1007/s11920-000-0012-8
[16] National Institute on Drug Abuse (NIDA), “Principles of Drug Addiction Treatment: A Research Based Guide,” US Department of Health and Human Services, Washington DC, NIH Publication No. 00.-4180, 2000.
[17] Substance Abuse and Mental Health Services Administration (SAMHSA), “Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction,” A Treatment Improvement Protocol, TIP 40. 2004.
http://www.kap.samhsa.gov/products/manuals/index.htm
[18] SAMHSA (Substance Abuse and Mental Health Services Administration), “Medication Assisted Treatment for Opioid Addiction in Opioid Treatment Programs,” Treatment Improvement Protocol (TIP) 43. 2005; DHHS Publication No. 05-4048. Rockville Maryland.
http://www.dpt.samhsa.gov/reports/index.htm
[19] T. F. Kresina, K. Hoffman and R. Lubran, “A Pilot Hepatitis Vaccination Program for Substance Abuse Treatment Settings,” The 2005 CDC HCV Prevention Conference, Washington DC, 5-9 December 2005, p. 21.
http://www.cdc.gov/hepatitis/Resources/MtgsConf/NatVHPrevConf2005/Agenda-NVHPC2005.pdf
[20] T. F. Kresina, C. Maxwell, M. W. Parrino and R. Lubran, “Testing and Counseling for Hepatitis B, Hepatitis C, and HIV Infections in Opioid Treatment Programs (OTP’s). Summary Results from Two Surveys,” The 2005 CDC HCV Prevention Conference, Washington DC, 5-9 December 2005, p. 17.
http://www.cdc.gov/hepatitis/Resources/MtgsConf/NatVHPrevConf2005/Agenda-NVHPC2005.pdf
[21] M. A. Bachhuber and C. O. Cunningham, “Changes in Testing for Human Immunodeficiency Virus, Sexually Transmitted Infections, and Hepatitis C Virus in Opioid Treatment Programs,” The Journal of the American Medical Association, Vol. 310, No. 24, 2013, pp. 2671-2672.
http://dx.doi.org/10.1001/jama.2013.278456
[22] J.A. Frimpong, “Missed Opportunities for Hepatitis C Testing in Opioid Treatment Programs,” American Journal of Public Health, Vol. 103, No. 6, 2013, pp. 1028-1030. http://dx.doi.org/10.2105/AJPH.2012.301129
[23] B. R. Edlin, T. F. Kresina and D. B. Raymond, “Care for Hepatitis C Disease and Barriers to Care among Injection Drug Users,” Clinical Infectious Diseases, Vol. 40, Suppl. 3, 2005, pp. S276-S285. http://dx.doi.org/10.1086/427441
[24] M. Backmund, K. Meyer and C. Henkel, “Risk Factors and Predictors of Human Immunodeficiency Virus Infection Among Injection Drug Users,” European Addiction Research, Vol. 11, No. 3, 2005, pp. 138-144.
http://dx.doi.org/10.1159/000085549
[25] I. Kuo, S. G. Sherman, D. L. Thomas and S. A. Strathdee, “Hepatitis B Virus Infection and Vaccination Among Young Injection and Non-Injection Drug Users: Missed Opportunities to Prevent Infection,” Drug and Alcohol Dependence, Vol. 73, No. 1, 2004, pp. 69-78.
http://dx.doi.org/10.1016/j.drugalcdep.2003.10.007
[26] J. E. Zweben, “Hepatitis C: Education and Counseling Issues,” Journal of Addictive Diseases, Vol. 20, No. 1, 2001, pp. 33-42.
http://dx.doi.org/10.1300/J069v20n01_04
[27] D. A. Fiellin, R. A. Rosenheck and T. R. Kosten, “Coordination of Medical Care and Opioid Dependence Treatment in Primary Care: A Case Report,” Substance Abuse, Vol. 24, No. 1, 2003, pp. 24:43-46.
[28] C. Bachireddy, C. S. Soule, J. M. Izenberg, S. Dvoryak, K. Dumchev and F. L. Altice, “Integration of Health Services Improves Multiple Healthcare Outcomes Among HIV-Infected People Who Inject Drugs in Ukraine,” Drug and Alcohol Dependence, Vol. 143, 2014, pp. 106-114.
http://dx.doi.org/10.1016/j.drugalcdep.2013.09.020
[29] National Institutes of Health (NIH), Consensus Development Conference Statement, “Management of Hepatitis C: 2002,” Final Statement August 26, 2002.
http://consensus.nih.gov
[30] M. Schaefer, A. Heinz and M. Backmund. “Treatment of Chronic Hepatitis C in Patients with Drug Dependence: Time to Change the Rules?” Addiction, Vol. 99, No. 9, 2004, pp. 1167-1175.
http://dx.doi.org/10.1111/j.1360-0443.2004.00821.x
[31] B. R. Edlin, K. H. Seal and J. Lorvick, “Is It Justifiable to Withhold Treatment for Hepatitis C From Illicit-Drug Users?” New England Journal of Medicine, Vol. 345, No. 3, 2001, pp. 211-214.
http://dx.doi.org/10.1056/NEJM200107193450311
[32] G. J. Dore and D. L. Thomas, “Management and Treatment of Injection Drug Users with Hepatitis C Virus (HCV) Infection and HCV/Human Immunodeficiency Virus Coinfection,” Seminars in Liver Disease, Vol. 25, No. 1, 2005, pp. 18-32. http://dx.doi.org/10.1055/s-2005-864779
[33] R. C. Botero, “Should Patients with Chronic Hepatitis C Infection Be Transplanted?” Transplantation Proceedings, Vol. 36, No. 5, 2004, pp. 1449-1454.
http://dx.doi.org/10.1016/j.transproceed.2004.06.003
[34] Centers for Disease Control and Prevention (CDC), “Recommendations for Prevention and Control of Hepatitis C Virus (HCV) Infection and HCV-Related Chronic Disease,” Morbidity and Mortality Weekly Report, Vol. 47, No. RR-19, 1998, pp. 1-39.
[35] G. L. Davis and J. R. Rodrigue, “Treatment of Chronic Hepatitis C in Active Drug Users,” New England Journal of Medicine, Vol. 345, No. 3, 2001, pp. 215-217.
http://dx.doi.org/10.1056/NEJM200107193450312
[36] J. J. McCarthy and N. Flynn, “Hepatitis C in Methadone Maintenance Patients: Prevalence and Public Policy Implications,” Journal of Addictive Diseases, Vol. 20, No. 1, 2001, pp. 19-31.
http://dx.doi.org/10.1300/J069v20n01_03
[37] M. D. Stein, J. Maksad and J. Clarke, “Hepatitis C Disease among Injection Drug Users: Knowledge, Perceived Risk and Willingness to Receive Treatment,” Drug and Alcohol Dependence, Vol. 61, No. 3, 2001, pp. 211-215.
http://dx.doi.org/10.1016/S0376-8716(00)00144-7
[38] United States Department of Health and Human Services, “Combating the Silent Epidemic of Viral Hepatitis. Action Plan for the Prevention, Care and Treatment of Viral Hepatitis,” 2011.
http://www.hhs.gov/ash/initiatives/hepatitis/actionplan_viralhepatitis2011.pdf
[39] US Preventive Services Task Force, “Screening for Hepatitis C Virus Infection in Adults: Final Recommendation Statement,” AHRQ Publication No. 12-05174-EF-2, 2013.
http://www.uspreventiveservicestaskforce.org/uspstf12/hepc/hepcfinalrs.htm.
[40] C. K. Aitken, M. Kerger and N. Crofts, “Peer-Delivered Hepatitis C Testing and Counseling: A Means of Improving the Health of Injection Drug Users,” Drug and Alcohol Review, Vol. 21, No. 1, 2002, pp. 33-37.
http://dx.doi.org/10.1080/09595230220119327
[41] A. H. Talal, R. B. Dimova, R. Seewald, R. H. Peterson, M. Zeremski and D. C. Perlman, “Assessment of Methadone Clinic Staff Attitudes toward Hepatitis C Evaluation and Treatment,” Journal of Substance Abuse Treatment, Vol. 44, No. 1, 2013, pp. 115-119.
http://dx.doi.org/10.1016/j.jsat.2012.01.010
[42] S. Mauss, F. Berger, J. Goelz, B. Jacob and G. Schmutz, “A Prospective Controlled Study of Interferon-Based Therapy of Chronic Hepatitis C in Patients on Methadone Maintenance,” Hepatology, Vol. 40, No. 1, 2004, pp. 120-124.
http://dx.doi.org/10.1002/hep.20279
[43] M. Schaefer, F. Schmidt and C. Folwaczny, “Adherence and Mental Side Effects During Hepatitis C Treatment with Interferon Alpha and Ribavirin in Psychiatric Risk Groups,” Hepatology, Vol. 37, No. 2, 2003, pp. 443-451.
http://dx.doi.org/10.1053/jhep.2003.50031
[44] D. H. Van Thiel, A. Anantharaju and S. Creech, “Response to Treatment of Hepatitis C in Individuals with a Recent History of Intravenous Drug Abuse,” American Journal of Gastroenterology, Vol. 98, No. 10, 2003, pp. 2281-2288.
http://dx.doi.org/10.1016/S0002-9270(03)00708-1
[45] D. L. Sylvestre, A. H. Litwin, B. J. Clements and M. N. Gourevitch, “The Impact of Barriers to HCV Treatment in Recovering Heroin Users Maintained on Methadone,” Journal of Substance Abuse Treatment, Vol. 29, No. 3, 2005, pp. 159-165.
http://dx.doi.org/10.1016/j.jsat.2005.06.002
[46] A. H. Litwain, K. A. Harris, S. Nahvi, P. J. Zamor, I. J. Soloway and P. L. Tenore, “Successful Treatment of Chronic Hepatitis with Pegylated Interferon in Combination with Ribavirin in a Methadone Maintenance Treatment Program,” Journal of Substance Abuse Treatment, Vol. 37, No. 1, 2009, pp. 32-40.
http://dx.doi.org/10.1016/j.jsat.2008.09.009
[47] L. E. Taylor, S. E. Bowman, S. Chapman, N. Zaller, M. D. Stein and P. A. Cioe, “Treatment for Hepatitis C Virus Genotype 1 Infection in HIV-Infected Individuals on Methadone Maintenance Therapy,” Drug and Alcohol Dependence, Vol. 116, No. 1-3, 2011, pp. 233-237.
http://dx.doi.org/10.1016/j.drugalcdep.2010.11.016
[48] A. Charlebois, L. Lee, E. Cooper, K. Mason and J. Powis, “Factors Associated with HCV Antiviral Treatment Uptake among Participants of a Community-Based HCV Programme for Marginalized Patients,” Journal of Viral Hepatitis, Vol. 19, No. 12, 2012, pp. 836-842.
http://dx.doi.org/10.1111/j.1365-2893.2012.01648.x
[49] A. Saxon, W. Ling, M. Hillhouse, C. Thomas, A. Hasson and A. Ang, “Buprenorphine/Naloxone and Methadone Effects on Laboratory Indices of Liver Health: A Randomized Trial,” Drug and Alcohol Dependence, Vol. 128, No. 1-2, 2013, pp. 71-76.
http://dx.doi.org/10.1016/j.drugalcdep.2012.08.002
[50] D. B. Strader, T. Wright, D. L. Thomas and L. Seeff, “Diagnosis, Management and Treatment of Hepatitis C. AASLD Practice Guideline,” Hepatology, Vol. 39, No. 4, 2004, pp. 1147-1171. http://dx.doi.org/10.1002/hep.20119
[51] American Association for the Study of Liver Disease (AASLD), “Diagnosis, Management and Treatment of Hepatitis C, AASLD Practice Guideline,” Hepatology, Vol. 39, No. 4, 2004, pp. 1147-1171.
http://dx.doi.org/10.1002/hep.20119
[52] M. J. Alter, D. Kruszon-Moran and O. V. Nainan, “The Prevalence of Hepatitis C Infection in the United States, 1988 through 1994,” New England Journal of Medicine, Vol. 341, 1999, pp. 556-562.
http://dx.doi.org/10.1056/NEJM199908193410802
[53] C. Boesecke, H. Wedemeyer and J. K. Rockstroh, “Diagnosis and Treatment of Acute Hepatitis C Virus Infection,” Infectious Disease Clinics of North America, Vol. 26, No. 4, 2012, pp. 995-1010.
http://dx.doi.org/10.1016/j.idc.2012.08.011
[54] J. Grebely, G. V. Matthews and G. J. Dore, “Treatment of Acute HCV Infection,” Nature Reviews Gastroenterology & Hepatology, Vol. 8, 2011, pp. 265-274.
[55] G. Nunnari, A. Montineri, V. Portelli, F. Savalli, F. Fatuzzo and B. Cacopardo, “The Use of Peginterferon in Monotherapy or in Combination with Ribavirin for the Treatment of Acute Hepatitis C,” European Review for Medical and Pharmacological Sciences, Vol. 16, No. 8, 2012, pp. 1013-1016.
[56] B. Hajarizadeh, J. Grebely and G. J. Dore, “Case Definitions for Acute Hepatitis C Virus Infection: A Systematic Review,” Journal of Hepatology, Vol. 57, No. 6, 2012, pp. 1349-1360. http://dx.doi.org/10.1016/j.jhep.2012.07.007
[57] E. Jaeckel, M. Cornberg, H. Wedemeyer, et al., “Treatment of Acute Hepatitis with Interferon Alfa-2b,” New England Journal of Medicine, Vol. 345, No. 20, 2001, pp. 1452-1457. http://dx.doi.org/10.1056/NEJMoa011232
[58] H. Nomura, S. Sou, H. Tanimoto, T. Nagahama, Y. Kimura, J. Hayashi, H. Ishibashi and S. Kashiwagi, “Short-Term Interferon-Alpha Therapy for Acute Hepatitis C: A Randomized Controlled Trial,” Hepatology, Vol. 39, No. 5, 2004, pp. 1213-1219. http://dx.doi.org/10.1002/hep.20196
[59] T. Santantonio, “Treatment of Acute Hepatitis C,” Current Pharmaceutical Design, Vol. 10, No. 17, 2004, pp. 2077-2080. http://dx.doi.org/10.2174/1381612043384222
[60] S. M. Kamal, K. N. Moustafa, J. Chen, J. Fehr, A. A. Moneim, K. E. Khalifa, L. A. El Gohary, A. H. Ramy, M. A. Madwar, J. Rasenack and N. H. Afdha, “Duration of Peginterferon Therapy in Acute Hepatitis C: A Randomized Trial,” Hepatology, Vol. 43, No. 5, 2006, pp. 923-931.
http://dx.doi.org/10.1002/hep.21197
[61] J. Weigand, P. Buggisch, W. Boecher, S. Zeuzem, C. M. Gelbmann, T. Bergs, W. Kauffmann, B. Kallinowski, M. Cornberg, E. Jaeckel, H. Wedemeyer and M. Manns, “Early Monotherapy with Pegylated Interferon Alpha-2b for Acute Hepatitis C Infection: The HEP-NET Acute-HCV-II Study,” Hepatology, Vol. 43, No. 2, 2006, pp. 250-256.
http://dx.doi.org/10.1002/hep.21043
[62] D. L. Thomas, “Advances in the Treatment of Hepatitis C Virus Infection,” Topics in Antiviral Medicine, Vol. 20, No. 1, 2012, pp. 5-10.
[63] S. Sockalingam, A. Tseng, P. Giguere and D. Wong, “Psychiatric Treatment Considerations with Direct Acting Antivirals in Hepatitis C,” BMC Gastroenterolohy, Vol. 13, 2013, pp. 86-96.
http://dx.doi.org/10.1186/1471-230X-13-86
[64] “FDA Approves Sovaldi for Chronic Hepatitis C,” FDA New Release, US Food and Drug Administration, 6 December 2013.
[65] P. J. Pockros, “Nucleoside/Nucleotide Analogue Polymerase Inhibitors in Development,” Clinics in Liver Disease, Vol. 17, No. 1, 2013, pp. 105-110.
http://dx.doi.org/10.1016/j.cld.2012.09.007
[66] N. K. Martin, et al., “HCV Treatment for Prevention among People Who Inject Drugs: Modeling Treatment Scale-up in an Age of Direct Acting Antivirals,” Hepatology, Vol. 58, No. 5, 2013, pp. 1598-1609.
[67] J. Stephenson, “Former Addicts Face Barriers to Treatment for HCV,” The Journal of the American Medical Association, Vol. 285, No. 8, 2001, pp. 1003-1005.
http://dx.doi.org/10.1001/jama.285.8.1003
[68] M. Schafer, “Psychiatric Patients, Methadone Patients, and Earlier Drug Users Can Be Treated for HCV When Given Adequate Support Services,” Presentation at Digestive Disease Week, Atlanta, 20-23 May 2001.
[69] H. Hagan, H. Haynes, R. A. Willson, T. R. Jackson and E. R. Alexander, “Feasibility of Alpha-Interferon Administration to Opiate Addicts in a Methadone Treatment Setting,” Hepatology, Vol. 30, No. 4, 1999, pp. 624-629.
[70] D. L. Sylvestre, J. M. Loftis, P. Hauser, S. Genser, H. Cesari, N. Borek, T. F. Kresina, L. Seeff and H. Francis, “Co-Occurring Hepatitis C, Substance Use and Psychiatric Illness: Treatment Issues and Developing Integrated Models of Care,” Journal of Urban Health, Vol. 81, No. 4, 2004, pp. 719-734.
http://dx.doi.org/10.1093/jurban/jth153
[71] A. H. Litwin, K. M. Berg, X. Li, J. Hidalgo and J. H. Arnsten, “Rationale and Design of a Randomized Controlled Trial of Directly Observed Hepatitis C Treatment Delivered in Methadone Clinics,” BMC Infectious Diseases, Vol. 11, 2011, pp. 315-334.
http://dx.doi.org/10.1186/1471-2334-11-315
[72] R. D. Bruce, J. Eiserman, A. Acosta, C. Gote, J. K. Lim and F. L. Altice, “Developing a Modified Directly Observed Therapy Intervention for Hepatitis C Treatment in a Methadone Maintenance Program: Implications for Program Replication,” American Journal of Drug and Alcohol Abuse, Vol. 38, No. 3, 2012, pp. 206-212.
http://dx.doi.org/10.3109/00952990.2011.643975
[73] M. R. Stein, I. J. Soloway, K. S. Jefferson, R. J. Roose, J. H. Arnsten and A. H. Litwin, “Concurrent Group Treatment for Hepatitis C: Implementation and Outcomes in a Methadone Maintenance Treatment Program,” Journal of Substance Abuse Treatment, Vol. 43, No. 4, 2012, pp. 424-432. http://dx.doi.org/10.1016/j.jsat.2012.08.007
[74] C. L. Masson, K. L. Delucchi, C. McKnight, J. Hettema, M. Khalilli, A. Min, et al., “A Randomized Trial of a Hepatitis Care Coordination Model in Methadone Maintenance Treatment,” American Journal of Public Health, Vol. 103, No. 10, 2013, pp. e81-e88.
http://dx.doi.org/10.2105/AJPH.2013.301458
[75] N. Durier, C. Nguyen and L. J. White, “Treatment of Hepatitis C as Prevention: A Modeling Case Study in Vietnam,” PloS ONE, Vol. 7, No. 4, 2012, Article ID: e34548. http://dx.doi.org/10.1371/journal.pone.0034548
[76] S. M. Alavain, A. Mirahmadizadeh, M. Javanbakht, A. Keshtkaran, A. Heidari, A. Mashayekhi, S. Salimi and M. Hadian, “Effectiveness of Methadone Maintenance Treatment in Prevention of Hepatitis C Virus Transmission among Injection Drug Users,” Hepatitis Monthly, Vol. 13, No. 8, 2013, Article ID: e12411.
[77] Medecins Sans Frontiers, “Diagnosis and Treatment of Hepatitis C: A Technical Landscape. Opportunities to Revolutionise Care in Developing Countries,” April 2013.
http://www.msfaccess.org/our-work/hiv-aids/article/2024

  
comments powered by Disqus

Copyright © 2017 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.